e-learning
resources
Stockholm 2007
Tuesday 18.09.2007
Epidemiology of tuberculosis II
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Relapse and failure pulmonary tuberculosis patients have the chance of cure with major antituberculosis drugs
D. Saka, M. Aydogdu, F. Cimen, H. Calisir, M. Ogretensoy (Ankara, Istanbul, Turkey)
Source:
Annual Congress 2007 - Epidemiology of tuberculosis II
Session:
Epidemiology of tuberculosis II
Session type:
Thematic Poster Session
Number:
3825
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Saka, M. Aydogdu, F. Cimen, H. Calisir, M. Ogretensoy (Ankara, Istanbul, Turkey). Relapse and failure pulmonary tuberculosis patients have the chance of cure with major antituberculosis drugs. Eur Respir J 2007; 30: Suppl. 51, 3825
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 339s
Year: 2001
Evaluation of relapse and defaulter pulmonary tuberculosis patients
Source: Eur Respir J 2005; 26: Suppl. 49, 647s
Year: 2005
Reevaluation of treatment outcome of relapse and defaulter pulmonary tuberculosis cases
Source: Eur Respir J 2004; 24: Suppl. 48, 650s
Year: 2004
Clinical efficacy of new anti-TB drug ²tubelon² during complex chemotherapy in patients with first-time diagnosed destuctive pulmonary TB
Source: Eur Respir J 2006; 28: Suppl. 50, 8s
Year: 2006
Side-effect in the treatment of pulmonary tuberculosis by first-line drugs
Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities
Year: 2009
Predictors of treatment failure among pulmonary tuberculosis patients in Pakistan
Source: International Congress 2019 – Tuberculosis: from diagnosis to complications
Year: 2019
Diaskintest at patients after successful treatment of lung tuberculosis
Source: International Congress 2017 – Migrants and screening
Year: 2017
Isoniazid resistance is associated with delayed culture conversion during anti-tuberculosis treatment among patients with pulmonary tuberculosis
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018
Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen
Source: Eur Respir J 2002; 20: Suppl. 38, 359s
Year: 2002
The evaluation of the relapse or treatment interrupted pulmonary tuberculosis cases
Source: Eur Respir J 2006; 28: Suppl. 50, 21s
Year: 2006
Side effects of antituberculosis drugs in treatment of patients with newly detected pulmonary tuberculosis
Source: Eur Respir J 2007; 30: Suppl. 51, 197s
Year: 2007
Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis?
Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis
Year: 2008
Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011
Recurrence after successful treatment among patients with multidrug-resistant tuberculosis
Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
Year: 2011
Statin with standard antituberculosis regimen and mortality in hospitalized pulmonary tuberculosis
Source: International Congress 2019 – Tuberculosis: treatment and management
Year: 2019
The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen
Source: Annual Congress 2010 - Tuberculosis drug resistance
Year: 2010
Prevalence of MDR and XDR tuberculosis among patients with failure of re-treatment course
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008
Treatment results in patients with drug resistant pulmonary tuberculosis
Source: Eur Respir J 2002; 20: Suppl. 38, 612s
Year: 2002
The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Chemotherapy efficacy in TB patients resistant to major and reserve drugs
Source: Eur Respir J 2005; 26: Suppl. 49, 648s
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept